Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,644.27
(
-1.07%
)
US TECH 100
23,943.60
(
-0.78%
)
Dow Jones
46,331.82
(
-1.41%
)
Brent Oil
105.19
(
4.51%
)
Bitcoin
71,192.52
(
-3.72%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

dewophile

Send PM Follow Ignore
Followers 49
Posts 5519
Boards Moderated 0
Alias Born 07/19/2006

dewophile

Re: ThomasS post# 114680

Monday, 02/14/2011 9:23:10 AM

Monday, February 14, 2011 9:23:10 AM

Post# of 257253
at least one of the FOBs with sandoz was dropped because of poor commercial prospects, so i think it's safe to say at least one of the candidates was not an TNFalpha inhibitor

it would be interesting if BIIB hooked up with MNTA in FOBs - doug williams is at BIIB now and he was instrumental in enbrel's development while at immunex - he could then see the drug come full circle as a generic at BIIB :)
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now